Companies /Healthcare

Envista Holdings Corp

NYSE: NVST Medical Instruments & Supplies
$27.28
▼ $0.31 (−1.12%) today
Markets closed · 8:00pm ET

Q1 2026 Earnings

Reported May 6, 2026, 4:12pm ET · SEC source
$0.36
Beat +14.94%
EPS · est. $0.31
$705.5M
Beat +3.74%
Revenue · est. $680.1M
+0.5%
Beating market
NVST vs S&P since report
5 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−7%0+7%May 6May 7report 4:12pm ETearnings−0.3%−10.3%
−7%0+7%May 6May 7earnings−0.3%−10.3%
NVST −10.3%S&P 500 −0.3%
−7%0+7%May 6May 7report 4:12pm ETearnings−0.2%−10.3%
−7%0+7%May 6May 7earnings−0.2%−10.3%
NVST −10.3%NASDAQ −0.2%
−14%−7%0May 5May 14report 4:12pm ETearnings+1.9%−17.5%
−14%−7%0May 5May 14earnings+1.9%−17.5%
NVST −17.5%S&P 500 +1.9%
−14%−7%0May 5May 14report 4:12pm ETearnings+3.5%−17.5%
−14%−7%0May 5May 14earnings+3.5%−17.5%
NVST −17.5%NASDAQ +3.5%
−10.27%
Day of report
−0.21%
Next session
−1.77%
One week
+1.24%
30 days

S&P 500 over the same 30 days: +0.75%.

Did NVST Beat Earnings? Q1 2026 Results

Envista Holdings posted a strong first quarter for fiscal 2026, beating Wall Street expectations on both the top and bottom lines as broad-based momentum across its dental segments drove results well ahead of forecasts. The company reported adjusted diluted EPS of $0.36, clearing the $0.31 consensus estimate by 14.94%, while revenue of $705.50 million topped the $680.07 million consensus by 3.74% and grew 14.4% year over year. The standout driver was Equipment & Consumables, which delivered 11.5% core growth and saw GAAP operating margins expand sharply to 18.9% from 14.7% a year ago, contributing to a 50% year-over-year surge in adjusted EPS and a 25% climb in adjusted EBITDA to $98.90 million. The Envista Business System contributed 120 basis points of adjusted EBITDA margin expansion, lifting the margin to 14.0%. Despite some volatility in the stock following the report, management reaffirmed full-year 2026 guidance calling for core sales growth of 2% to 4% and adjusted diluted EPS in the range of $1.35 to $1.45, signaling confidence in the company's trajectory amid a complex macro backdrop.

Key Takeaways
  • 9.5% core revenue growth driven by customer engagement and new product commercialization
  • Envista Business System (EBS) contributed 100 bps of gross margin and 120 bps of adjusted EBITDA margin expansion
  • All major businesses delivered positive growth
  • Favorable currency translation contributing 4.3 percentage points to reported growth

“We delivered a good start to 2026, with first quarter results reflecting continued strong execution and progress in support of our strategic priorities.”

Envista CEO, on the earnings call

Forward Guidance & Outlook

Envista reaffirmed full-year 2026 guidance: core sales growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, adjusted diluted EPS of $1.35 to $1.45, and free cash conversion of approximately 100%. The company does not provide forward-looking estimates on a GAAP basis.

NVST YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$0$200.0M$400.0M$600.0M$616.9M$705.5MRevenue$336.0M$390.1MGross Profit$39.0M$62.5MOperating Income$18.0M$38.7MNet Income
$0$200.0M$400.0M$600.0MRevenueGross ProfitOperating IncomeNet Income

NVST Revenue by Segment

Specialty Products & Technologies$457.8M+8.4%
Equipment & Consumables$247.7M+11.5%

Figures from SEC filings and company reports. Not investment advice.